Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021

Hospital-acquired pneumonia (HAP) drugs market

Market research analysts at Technavio predict that the global hospital-acquired pneumonia (HAP) drugs market will grow steadily during the forecast period and post a CAGR of more than 2% by 2021. This market research analysis identifies the inadequate healthcare infrastructure in the developing countries as one of the primary growth factors for this market.

HAP drugs market drivers

The inadequate healthcare infrastructure and the lack of proper hygiene in developing countries are the major problems which lead to healthcare-associated infections. Infection control procedure and other hygienic necessities are influenced by several factors such as poor infrastructure, the lack of financial resources, and overcrowded hospitals. Inadequate sanitary conditions and the inappropriate use of sanitary drugs are some of the artificial factors leading to the development of MDR microorganisms, consequently rising HAP cases. This will increase the need for HAP drugs, which will, in turn, augment the growth prospects for the HAP drugs market.

HAP drugs market trends

The market research report identifies the emergence of combination therapy for the treatment of HAP as one of the key trends behind the growth of the HAP drugs market. Monotherapy is deemed to be the common treatment for pneumonia but it has been observed that combination treatment provides better results and is the appropriate and desirable treatment. The increased resistance of pathogens to the administered drug triggers the demand and implementation of combination drugs. Combination therapy reduces the chances of resistance developed by the bacteria and provides a broad spectrum of coverage, consequently propelling the growth of the market.

HAP drugs market: Competitive landscape and key vendors

The HAP drugs market is fragmented due to the presence of vendors of various sizes and market shares. It is dominated by few key players that set competitive pricing strategies followed in the market. The vendors in the market mainly compete based on the pricing strategies and the product portfolio offered to customers. Increased investments in R&D and M&A will impact the vendors’ performance and also the market’s competitive environment.

The leading vendors in the HAP drugs market

• GlaxoSmithKline
• Merck
• Mylan
• Novartis
• Pfizer
• Teva Pharmaceutical Industries

HAP drugs market  segmentation by drug type 

• Antibacterial
• Antiviral
• Antifungal

Bacteria is the major cause of HAP and there are numerous players in the market who produce antibacterial drugs mainly due to the availability of generic versions of the drugs. According to this market research report, the antibacterial segment accounted for the major shares and dominated the HAP drugs market during 2016. Factors such as the increased usage of antibacterial drugs for the prevention and treatment of bacterial infections will contribute to the growth of this market segment in the coming years.

HAP drugs market based on geographical segmentation

• Americas
• APAC
• EMEA

This market study estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the market by 2021. This is mainly due to the high prevalence of pneumonia and hospital acquired infection and the relevant steps taken by the governments of countries in this region. Additionally, the presence of numerous key vendors that has enabled easy access and has improved the quality of treatment available to the consumers, will also fuel the growth prospects of the HAP drugs market in this region.

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global hospital-acquired pneumonia (HAP) drugs market?
• What are the key market trends impacting the growth of the global hospital-acquired pneumonia (HAP) drugs market?
• What are the challenges to market growth?
• Who are the key vendors in the global hospital-acquired pneumonia (HAP) drugs market?
• What are the market opportunities and threats faced by the vendors in the global hospital-acquired pneumonia (HAP) drugs market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global hospital-acquired pneumonia (HAP) drugs market? 

Technavio also offers customization on reports based on specific client requirement.